Somatic mutations in tumor-infiltrating lymphocytes impact on antitumor immunity.

doi:10.1073/pnas.2320189121

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Somatic mutations in tumor-infiltrating lymphocytes impact on antitumor immunity.

Proceedings of the National Academy of Sciences of the United States of America - 27 Aug 2024

Mukohara Fumiaki, Iwata Kazuma, Ishino Takamasa, Inozume Takashi, Nagasaki Joji, Ueda Youki, Suzawa Ken, Ueno Toshihide, Ikeda Hideki, Kawase Katsushige, Saeki Yuka, Kawashima Shusuke, Yamashita Kazuo, Kawahara Yu, Nakamura Yasuhiro, Honobe-Tabuchi Akiko, Watanabe Hiroko, Dansako Hiromichi, Kawamura Tatsuyoshi, Suzuki Yutaka, Honda Hiroaki, Mano Hiroyuki, Toyooka Shinichi, Kawazu Masahito, Togashi Yosuke

Abstract excerpt

Immune checkpoint inhibitors (ICIs) exert clinical efficacy against various types of cancers by reinvigorating exhausted CD8+ T cells that can expand and directly attack cancer cells (cancer-specific T cells) among tumor-infiltrating lymphocytes (TILs). Although some reports have identified somatic mutations in TILs, their effect on antitumor immunity remains unclear. In this study, we successfully established 18...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CD8-Positive T-Lymphocytes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immune Checkpoint Inhibitors

Share to Lymphocytes, Tumor-Infiltrating

Share to Melanoma

Share to Mice

Share to Mice, Knockout

Share to Mutation

Share to Tumor Necrosis Factor alpha-Induced Protein 3

Source

Open in PubMed Open full text

Identifiers

PMID: 39167601
DOI: 10.1073/pnas.2320189121
PMCID: PMC11363295

Genes

SH2D2A
TNFAIP3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Somatic mutations in tumor-infiltrating lymphocytes impact on antitumor immunity.PMID 39167601Read ↗

Integrated genomic analysis identifies a genetic mutation model predicting response to immune checkpoint inhibitors in melanoma.Semantic proximity Read ↗

The immune response-related genomic alterations in patients with malignant melanoma.Semantic proximity Read ↗

Somatic <i>TYK2</i> activating mutations in tumor-infiltrating T cells promote anti-cancer immunitySemantic proximity Read ↗

Novel Molecular Determinants of Response or Resistance to Immune Checkpoint Inhibitor Therapies in Melanoma.Semantic proximity Read ↗

Genetic basis for clinical response to CTLA-4 blockade in melanoma.Semantic proximity Read ↗

Association of KMT2C/D loss-of-function variants with response to immune checkpoint blockades in colorectal cancer.Semantic proximity Read ↗

Prevalence of PRKDC mutations and association with response to immune checkpoint inhibitors in solid tumors.Semantic proximity Read ↗

Revolutionizing Cancer Therapy: A Comprehensive Review of Immune Checkpoint InhibitorsSemantic proximity Read ↗

CD4 T cells and toxicity from immune checkpoint blockadeSemantic proximity Read ↗

SETBP1 mutation determines sensitivity to immune checkpoint inhibitors in melanoma and NSCLC.Semantic proximity Read ↗

Massively parallel interrogation of human functional variants modulating cancer immunosurveillance.Semantic proximity Read ↗

KMT2A/C mutations function as a potential predictive biomarker for immunotherapy in solid tumorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.